HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours

ABSTRACT: Abstract INTRODUCTION: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumours. Larotrectinib, a highly selective TRK inhibitor, demonstrated an objective response rate (ORR) of 75% across 206 evaluable patients with various non-primary CNS cancers (Hong et al, ASCO 2021). We report long-term data on larotrectinib-treated paediatric patients with TRK fusion-positive primary CNS tumours. METHODS: Patients aged <18 years with TRK fusion-positive primary CNS tumours enrolled in two clinical trials (NCT02637687, NCT02576431) were included. Larotrectinib was administered at 100 mg/m2 (maximum: 100 mg) twice-daily. Response was investigator-assessed per RECIST v1.1 and RANO. RESULTS: As of July 2021, 28 patients with TRK fusion-positive primary CNS tumo

SUBMITTER:  

PROVIDER: S-EPMC9165410 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature